Regulatory Risk to Price: Medical Device Diligence That Protects Buyers
A device recall can remove years of earnings. Philips' CPAP recall grew to 5.5 million devices and led to settlements worth billions, so FDA status and recall history must show in the price, the escrow and the indemnity terms.
Medical device companies make products that doctors and patients use for diagnosis and treatment. In the US, the Food and Drug Administration (FDA) must clear or approve most of these products before a company can sell them. Thus, regulatory status is a direct part of the value of the business. In June 2021, Philips started a recall of its CPAP and BiPAP sleep and breathing devices. Foam inside the devices could break down and go into the airway of the user. The repair and replacement program grew to 5.5 million devices. By fall 2023, the FDA had more than 116,000 complaint reports, which included at least 561 deaths (Fierce Biotech, 2024). The cost was large. In 2023, Philips agreed to pay more than USD 600 million to settle economic loss claims. In 2024, it agreed to pay USD 1.1 billion to settle personal injury claims. That provision caused an operating loss of EUR 834 million in the first quarter of 2024 (Fierce Biotech, 2024). Philips also signed a consent decree with the US Department of Justice and the FDA. Philips stopped the sale of new sleep and respiratory devices in the US. It can start these sales again only when it meets the decree conditions (PharmExec, 2024). One quality problem in one product line became an earnings problem for many years. For a buyer, this type of risk must show in the price.
Part of our Due Diligence series. For the full picture, see our due diligence services in India.
Why Regulatory Status Drives Value
In the US, most devices go to market through one of two pathways. The 510(k) pathway lets a company show that its device is similar to a device that is already on the market. Premarket Approval (PMA) applies to high-risk devices and needs clinical data. A PMA takes more time and money. But it also gives a stronger barrier against competitors. Many target forecasts include products that do not have clearance yet. That part of the revenue depends on an FDA decision. A delay of one year moves the cash flows to a later date and decreases their present value. What this means: Do not pay the same multiple for pipeline revenue and for revenue from cleared products. Show the two separately in the model and apply a probability and a timeline to the pipeline.
Where Recall Risk Hides in the Numbers
The cost of a recall is more than the cost of replacement products. It includes logistics, legal claims, lost sales during a sales stop, and the cost to repair the quality system. Most of these costs occur after closing. Historical EBITDA does not show them. Before signing, a buyer must check: • FDA inspection history. Form 483 observations and warning letters for each facility. • Complaint trends. Complaints and Medical Device Reports (MDRs) for each product, for the last three to five years. • Recall history. Each recall and field correction, with its root cause and its closure status. • Warranty and returns reserves. Compare the reserves with the actual claims. • Supplier quality. Single-source parts and the results of supplier audits.
How Findings Go Into the Deal Terms
• Price. Decrease EBITDA, or the multiple, for products with open quality problems. • Specific indemnity. Ask the seller to cover known recall and quality matters. Rep and warranty insurance does not cover known issues. • Escrow. Hold back a part of the price until a clearance or a remediation is complete. • Earn-out. Pay a part of the price only when the FDA clears a pipeline product. Write the efforts duties in specific terms, because regulatory milestones often cause disputes.
Where MARC Comes In
• Separate cleared revenue from pipeline revenue and value each on its own basis. • Calculate recall, warranty and remediation exposure, and convert it into price, escrow and indemnity terms. • Test complaint, return and warranty data against the reported reserves. Speak with MARC's advisory team before you sign your next medical device deal.
FAQs
What is the difference between 510(k) clearance and PMA? A 510(k) shows that a device is similar to a device already on the market. A PMA applies to high-risk devices and needs clinical evidence. A PMA costs more, but it gives a stronger barrier against competitors. Why does recall history change the valuation? A recall can cause settlements, a sales stop and quality repair costs for many years. Historical EBITDA does not include these costs, so the buyer must add them to the price analysis. Does rep and warranty insurance cover a recall? Not if the buyer knew about the problem before signing. Known matters need a specific indemnity, an escrow or a price adjustment.
Key Takeaway
In medical devices, the quality system is part of the asset. A weak quality system is a liability that the balance sheet does not show. Buyers must test it with the same care that they apply to revenue.
Free Self-Assessment
India Market Entry & Feasibility Scorecard
Get an instant readiness score across market, regulatory, financial, and operational dimensions — 4 minutes, free.
Go deeper on Due Diligence
This article is one of several on the topic. Start with our due diligence services in India page, or keep reading:
About MARC Analytics Team
Our research team comprises experienced financial analysts and consultants with over 50+ years of combined experience.
View all articles →Price Regulatory and Recall Risk Before You Sign
Speak with MARC's advisory team before you sign your next medical device deal.
